To view the PDF file, sign up for a MySharenet subscription.

BIO - BioScience Brands Limited - Sale of Nutrimax Brand

Release Date: 31/05/2012 12:00
Code(s): BIO
Wrap Text

BIO - BioScience Brands Limited - Sale of Nutrimax Brand BIOSCIENCE BRANDS LIMITED (Incorporated in the Republic of South Africa) (Registration Number: 2005/005805/06) Share code: BIO ISIN code: ZAE000115036 ("BioScience") SALE OF NUTRIMAX BRAND 1. Introduction Shareholders are advised that BioScience has disposed of its Nutrimax Brand ("Nutrimax") together with stock, valued at the lower of cost or net realisable value, to Akacia Healthcare (Proprietary) Limited ("Akacia"), with effect from 1 June 2012 ("the Transaction"). BioScience originally acquired Nutrimax during June 2009 for R1,6 million. Nutrimax is a range of health bars. 2. Details of the Transaction The consideration to be received by BioScience for the sale of Nutrimax in terms of the Transaction will be R2.0 million, which is equal to the annualised turnover of the current financial year of Nutrimax, plus an additional maximum amount of R600 000 in respect of stock to be valued at a lower of cost or net realisable value. Such aggregate sale proceeds not exceeding R2,6 million will be settled by way of a cancellation of debt owing by BioScience to Akacia and/or its subsidiaries or related companies.. The terms of the Transaction also provide that subject to the conditions specified in 2.1 and 2.2 below, BioScience has the right but not the obligation to reacquire Nutrimax from Akacia one year following the effective date but not more than two years after the effective date, at its discretion, subject to the following conditions: 2.1 there should be no amounts owing to Akacia by BioScience that are either overdue or outside of the terms of the Management Agreement and Loan Agreement signed by Akacia and BioScience on 5 April 2011, or any other subsequent agreement entered into between Akacia and BioScience, unless both parties agree to waiver; 2.2. the repurchase price for Nutrimax would be the annualised turnover of the current financial year of Nutrimax plus the value of stock valued at lower of cost or net realisable value. 3. Rationale for the Transaction The Board of BioScience has resolved to dispose of Nutrimax in order to maximise the resources and focus of BioScience on its more prominent brands in the current financial year. In this regard, the Nutrimax brand, which requires an advertising and support program, would in all likelihood be adversely affected. In this regard, Akacia, which has a close business relationship with BioScience and available resources, has agreed to the Transaction which, inter alia, will involve the ongoing promotion and advertising of Nutrimax therefore ensuring the continued growth of Nutrimax. Depending on growth of BioScience`s other brands and hence profitability, BioScience may repurchase Nutrimax as explained in paragraph 2 above. 4. Categorisation of the Transaction In terms of the Listings Requirements of the Johannesburg Stock Exchange Limited, the Transaction is classified as a Category 2 transaction for Bioscience, as well as a small related party transaction. 5. Illustrative Financial Effects of the Transaction The unaudited pro forma financial effects set out below are included for the purpose of illustrating the effect on BioScience shareholders, of the sale of Nutrimax, on BioScience`s historical earnings ("EPS"), headline earnings ("HEPS"), net asset value ("NAV") and net tangible asset value ("NTAV") per BioScience ordinary share for the 6 months ended 31 December 2011 and as at 31 December 2011 respectively. These unaudited pro forma financial effects: - are the responsibility of the directors; - are presented for illustrative purposes only and have not been reviewed by BioScience`s auditors; - may, because of their nature, not give a fair reflection of BioSicence` financial results, changes in equity, cash flows or financial position after the Transaction; and - do not necessarily represent or indicate sustainable earnings or future financial positions. Unaudited Unaudited Percentage Before the After the change Transaction Transaction
EPS and diluted EPS (cents) (0.008) (0.004) 50% HEPS and diluted HEPS (cents) (0.008) (0.020) (150%) NAV per share (cents) 0.68 0.69 1% NTAV per share (cents) (0.75) (0.67) 11% Notes and assumptions: 1 The financial information has been extracted from the published interim financial results of BioScience for the period ended 31 December 2011. 2 The "After the Transaction" column reflects the effects of the sale of Nutrimax on EPS, diluted EPS, HEPS and diluted HEPS for the 6 month period ended 31 December 2011 based on the following assumptions: i that the sale of Nutrimax was effective 1 July 2011; ii the earnings have been adjusted to eliminate the revenue and costs actually earned and incurred during the period related to Nutrimax, and to reflect the profit on the disposal of Nutrimax of R420,000. 3 The "After the Transaction" column reflects the effects of the sale of Nutrimax on NAV and NTAV at 31 December 2011 based on the following assumptions: i that the sale of Nutrimax was effective 31 December 2011; ii that the proceeds of R2 million from the sale of Nutrimax and R345 000 as at 31 December 2011 from the purchase of stock on hand were offset against the amount owed to Akacia as current portion of borrowings; iii the profit on disposal of Nutrimax of R420,000 was recognised. 4 Transaction costs were not accounted for as they are immaterial. 31 May 2012 Designated Advisor PricewaterhouseCoopers Corporate Finance (Proprietary) Limited Date: 31/05/2012 12:00:02 Supplied by www.sharenet.co.za Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.

Share This Story